These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 33494127

  • 1. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
    Zhang WR, Du YY, Guo CY, Zhou HX, Lin JY, Meng XH, Mo HY, Luo DH.
    Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
    [Abstract] [Full Text] [Related]

  • 2. The serological diagnostic value of EBV-related IgA antibody panels for nasopharyngeal carcinoma: a diagnostic test accuracy meta-analysis.
    Liu H, Lei L, Song S, Geng X, Lin K, Li N, Chen W, Peng J, Ren J.
    BMC Cancer; 2024 Sep 07; 24(1):1115. PubMed ID: 39244576
    [Abstract] [Full Text] [Related]

  • 3. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
    Xia C, Zhu K, Zheng G.
    Int J Clin Exp Pathol; 2015 Sep 07; 8(12):16104-10. PubMed ID: 26884888
    [Abstract] [Full Text] [Related]

  • 4. Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.
    Zhang L, Tang LQ, Chen QY, Liu H, Guo SS, Liu LT, Guo L, Mo HY, Zhao C, Guo X, Cao KJ, Qian CN, Zeng MS, Shao JY, Sun Y, Ma J, Hong MH, Mai HQ.
    Oncotarget; 2016 Feb 02; 7(5):6221-30. PubMed ID: 26716900
    [Abstract] [Full Text] [Related]

  • 5. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.
    Cancer; 2004 Mar 15; 100(6):1162-70. PubMed ID: 15022282
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB, Zhang N, Chen DM, Yang XL, Chen BH, Zhao H, Lu RL, Chen Y, Fu LW.
    Radiother Oncol; 2019 Mar 15; 132():223-229. PubMed ID: 30366725
    [Abstract] [Full Text] [Related]

  • 8. Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status.
    Peng H, Chen L, Zhang Y, Guo R, Li WF, Mao YP, Tan LL, Sun Y, Zhang F, Liu LZ, Tian L, Lin AH, Ma J.
    Oncotarget; 2016 Apr 26; 7(17):24208-16. PubMed ID: 27008701
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
    Hu J, Li Y, Li H, Shi F, Xie L, Zhao L, Tang M, Luo X, Jia W, Fan J, Zhou J, Gao Q, Qiu S, Wu W, Zhang X, Liao W, Bode AM, Cao Y.
    Theranostics; 2020 Apr 26; 10(26):11921-11937. PubMed ID: 33204320
    [Abstract] [Full Text] [Related]

  • 11. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
    Cai YL, Zheng YM, Cheng JR, Wang W, Zhang YN, Wang WH, Wu YS, Zhong WM, Li J, Mo YK.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar 26; 30(3):509-11. PubMed ID: 20335122
    [Abstract] [Full Text] [Related]

  • 12. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
    Yao JJ, Lin L, Jin YN, Wang SY, Zhang WJ, Zhang F, Zhou GQ, Cheng ZB, Qi ZY, Sun Y.
    Cancer Sci; 2017 Aug 26; 108(8):1640-1647. PubMed ID: 28603915
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
    Sun XS, Chen WH, Liu SL, Liang YJ, Chen QY, Guo SS, Wen YF, Liu LT, Xie HJ, Tang QN, Li XY, Yan JJ, Mai HQ, Tang LQ.
    Cancer Med; 2019 Aug 26; 8(9):4214-4225. PubMed ID: 31210417
    [Abstract] [Full Text] [Related]

  • 18. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification.
    Lee VH, Kwong DL, Leung TW, Choi CW, O'Sullivan B, Lam KO, Lai V, Khong PL, Chan SK, Ng CY, Tong CC, Ho PP, Chan WL, Wong LS, Leung DK, Chan SY, So TH, Luk MY, Lee AW.
    Int J Cancer; 2019 Apr 01; 144(7):1713-1722. PubMed ID: 30192385
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.